We are live on ! Find out more
LCP

Lamond Capital Partners Portfolio holdings

AUM $14.3M
1-Year Est. Return 30.74%
This Fund
S&P 500
This Quarter Est. Return
+37.01%
1 Year Est. Return
-30.74%
3 Year Est. Return
+54.28%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$153M
AUM Growth
+$62.6M
Cap. Flow
+$44M
Cap. Flow %
28.82%
Top 10 Hldgs %
90.21%
Holding
24
New
12
Increased
2
Reduced
1
Closed
9

Top Buys

Rank Stock Value
1
KITE
Kite Pharma, Inc.
KITE
+$15.4M
2
GILD icon
Gilead Sciences
GILD
+$14.1M
3
PBYI icon
Puma Biotechnology
PBYI
+$12.2M
4
BLOX
Infoblox Inc
BLOX
+$12.1M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$9.8M

Top Sells

Rank Stock Value
1
LNKD
LinkedIn Corporation
LNKD
+$10.6M
2
AMGN icon
Amgen
AMGN
+$9.83M
3
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$9.43M
4
KING
KING DIGITAL ENTMT PLC ORD SHS (IRL)
KING
+$9.13M
5
CIEN icon
Ciena
CIEN
+$6.88M

Sector Composition

Rank Sector Weight
1 Healthcare 60.16%
2 Technology 38.91%
3 Miscellaneous 0.94%
4 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLOX
1
DELISTED
Infoblox Inc
BLOX
$30.2M 19.8%
1,495,906
+722,996
+94% +$12.1M
KITE
2
DELISTED
Kite Pharma, Inc.
KITE
$21.1M 13.82%
+365,900
New +$15.4M
BLUE
3
DELISTED
bluebird bio
BLUE
$13.5M 8.85%
+11,378
New +$7.6M
RALY
4
DELISTED
RALLY SOFTWARE DEV CORP
RALY
$13.2M 8.66%
1,163,626
+370,676
+47% +$3.85M
GILD icon
5
Gilead Sciences
GILD
$187B
$12.8M 8.39%
+135,870
New +$14.1M
OREX
6
DELISTED
Orexigen Therapeutics, Inc.
OREX
$11.5M 7.5%
+189,100
New +$9.5M
PBYI icon
7
Puma Biotechnology
PBYI
$493M
$10.4M 6.82%
+55,005
New +$12.2M
GWPH
8
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$9.09M 5.95%
+134,230
New +$9.8M
BMRN icon
9
BioMarin Pharmaceuticals
BMRN
$12.9B
$8.3M 5.44%
+91,840
New +$7.64M
CRM icon
10
Salesforce
CRM
$213B
$7.59M 4.97%
127,970
-54,070
-30% -$3.19M
AOL
11
DELISTED
AOL INC COMMON STOCK
AOL
$5.95M 3.9%
+128,850
New +$5.67M
RARE icon
12
Ultragenyx Pharmaceutical
RARE
$1.51B
$3.42M 2.24%
+77,940
New +$3.57M
RNG icon
13
RingCentral
RNG
$6.13B
$2.41M 1.58%
+161,424
New +$2.03M
OCUL icon
14
Ocular Therapeutix
OCUL
$2.34B
$1.75M 1.15%
+74,380
New +$1.25M
GEVA
15
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$1.43M 0.94%
+15,390
New +$1.21M
AMGN icon
16
Amgen
AMGN
$236B
– –
-70,000
Closed -$9.83M
CIEN icon
17
Ciena
CIEN
$45.5B
– –
-411,650
Closed -$6.88M
FTNT icon
18
Fortinet
FTNT
$115B
– –
-728,250
Closed -$3.68M
VIRX
19
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-6,286
Closed -$9.43M
FMI
20
DELISTED
Foundation Medicine, Inc.
FMI
– –
-130,053
Closed -$2.47M
NMBL
21
DELISTED
Nimble Storage, Inc.
NMBL
– –
-102,514
Closed -$2.66M
KING
22
DELISTED
KING DIGITAL ENTMT PLC ORD SHS (IRL)
KING
– –
-719,006
Closed -$9.13M
ZU
23
DELISTED
ZULILY INC CLASS A COMMON STOCK
ZU
– –
-105,230
Closed -$3.99M
LNKD
24
DELISTED
LinkedIn Corporation
LNKD
– –
-51,070
Closed -$10.6M

Similar funds

HCM
Hirzel Capital Management Dallas, Texas $15.1M AUM 5.29% 1-Year Est. Return
PPF
PartnerRe Principal Finance Greenwich, Connecticut $15.5M AUM 13.01% 1-Year Est. Return
PM
Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return
TSU
TD Securities (USA) New York $11M AUM 2.35% 1-Year Est. Return
RCMC
Rubric Capital Management (Connecticut) Stamford, Connecticut $6.44M AUM 43.01% 1-Year Est. Return
SCA
Strategic Capital Alternatives Gig Harbor, United States $6.3M AUM
GFWEV
G.F.W. Energy VII Irving, Texas $1.49M AUM 89.53% 1-Year Est. Return
USG2
Union Square GP 2004 New York $34.6M AUM

Lamond Capital Partners's Q4 2014 Portfolio in Review

As of Q4 2014, Lamond Capital Partners held 24 positions worth $153M, up 70% from $90.1M the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Lamond Capital Partners deployed $44M of net new capital in Q4 2014, opening 12 new positions and adding to 2 existing holdings. Its largest new stake was Kite Pharma, Inc.: 365,900 shares worth $21.1M.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 24% a quarter earlier, followed by Technology and Miscellaneous.

On the sell side, the largest reduction was Salesforce, an estimated $3.19M trimmed.

  • Lamond Capital Partners's largest Q4 2014 buy was Kite Pharma, Inc.: 365,900 shares worth $21.1M.
  • Lamond Capital Partners added most to Infoblox Inc in Q4 2014, an estimated $12.1M increase.
  • Lamond Capital Partners's biggest Q4 2014 reduction was Salesforce, cutting an estimated $3.19M.
  • Lamond Capital Partners fully exited LinkedIn Corporation in Q4 2014, selling an estimated $10.6M.
  • Lamond Capital Partners's ten largest holdings make up 90% of its $153M portfolio in Q4 2014.
  • Lamond Capital Partners opened 12 new positions and closed 9 in Q4 2014.
  • Lamond Capital Partners's portfolio value rose 70% quarter-over-quarter to $153M.

Based on Lamond Capital Partners's 13F filing for Q4 2014, filed 13 Feb 2015.